Pfizer and obesity drug

$Pfizer(PFE.US)$ usd 38.30. Pfizer's lotiglipron dropped, danuglipron still in the test pipeline for obesity drug. Alternative includes Novo Nordisk's Ozempic which is also at mid-stage testing (ref. 1).
Ref
1. https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-discontinue-development-obesity-drug-2023-06-26/